| 利妥昔单抗在造血干细胞移植治疗淋巴瘤中应用的研究进展 |
| |
| 引用本文： | 孙道萍. 利妥昔单抗在造血干细胞移植治疗淋巴瘤中应用的研究进展[J]. 白血病．淋巴瘤, 2014, 23(8): 503-506 |
| |
| 作者姓名： | 孙道萍 |
| |
| 作者单位： | 210029,南京医科大学第一附属医院血液科 |
| |
| 摘 要： | 由于毒性较低且具有抗淋巴瘤活性,利妥昔单抗被纳入淋巴瘤的移植治疗中.其不仅可提高疗效,减少移植后疾病复发,还可发挥免疫调节作用,有利于移植物抗宿主病的防治.文章对利妥昔单抗在自体和异基因造血干细胞移植治疗淋巴瘤中的应用作一综述.
|
| 关 键 词： | 淋巴瘤 利妥昔单抗 造血干细胞移植 移植物抗宿主病 |
Research progress of application of rituximab in hematopoietic stem cell transplantation for lymphoma |
| |
| Sun Daoping. Research progress of application of rituximab in hematopoietic stem cell transplantation for lymphoma[J]. Journal of Leukemia & Lymphoma, 2014, 23(8): 503-506 |
| |
| Authors: | Sun Daoping |
| |
| Affiliation: | .( Department of Hematology, the First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China) |
| |
| Abstract: | Owing to its low toxicity and high anti-lymphoma activity, rituximab has been applied in the transplantation for lymphoma. It can not only improve the therapeutic effect and reduce the recurrence of the disease, but also play a role in immunoregulation, which favors the prevention and treatment of graft- versus-host disease. In this paper, the application of rituximab in hematopoietic stem cell transplantation for lymphoma was reviewed. |
| |
| Keywords: | Lymphoma Rituximab Hematopoietic stem cell transplantation Graft-versus-host disease |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
